pd 173074 and azd4547
pd 173074 has been researched along with azd4547 in 11 studies
Research
Studies (11)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (90.91) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Ai, J; Dai, Y; Duan, W; Geng, M; Li, Y; Luo, C; Sun, Y; Xu, P; Zhao, B | 1 |
| Choi, JH; Kim, JH; Kwak, Y; Lee, SH; Oh, CH; Roh, EJ; Sim, T; Song, C; Yoo, KH | 1 |
| Cheng, W; Tian, X; Wang, M; Zhang, X | 1 |
| Dubiel, K; Dzwonek, K; Hucz-Kalitowska, J; Lamparska-Przybysz, M; Lipner, J; Magdycz, M; Olejkowska, P; Pieczykolan, J; Piórkowska, N; Popiel, D; Stańczak, A; Stańczak, PS; Wieczorek, M; Yamani, A; Zdżalik-Bielecka, D | 1 |
| Aldape, K; Brat, DJ; Castano, A; Ceccarelli, M; Chan, JM; Finocchiaro, G; Gao, Z; Golfinos, JG; Guha, A; Iavarone, A; Lasorella, A; Liu, EM; Mikkelsen, T; Niola, F; Pellegatta, S; Porrati, P; Qiu, K; Rabadan, R; Reichel, J; Riccardi, R; Singh, D; Sullivan, R; Zagzag, D; Zoppoli, P | 1 |
| Andrews, S; Balmanno, K; Blockley, L; Chell, V; Cook, SJ; Gavine, PR; Hampson, M; Little, AS; Wilson, M | 1 |
| Chalmers, AD; Doughton, G; Tapon, N; Wei, J; Welham, MJ | 1 |
| Bujak, A; Dymek, B; Dzwonek, K; Grygielewicz, P; Gunerka, P; Lamparska-Przybysz, M; Stanczak, A; Wieczorek, M; Zdzalik, D | 1 |
| Balek, L; Buchtova, M; Dosedelova, H; Gudernova, I; Jelinkova, I; Kozubik, A; Krejci, P; Kunova, M; Pivnicka, J; Roubalova, L; Vesela, I | 1 |
| Ebi, H; Faber, AC; Huynh, TG; Kita, K; Kitai, H; Kotani, H; Mino-Kenudson, M; Nanjo, S; Ooi, A; Yano, S | 1 |
| Bhole, A; Cowell, JK; Karp, J; Malek, S; Qin, H; Ren, M; Wu, Q | 1 |
Reviews
2 review(s) available for pd 173074 and azd4547
| Article | Year |
|---|---|
An overview of the binding models of FGFR tyrosine kinases in complex with small molecule inhibitors.
Topics: Humans; Protein Binding; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Small Molecule Libraries | 2017 |
Discovery and optimization of novel pyrazole-benzimidazole CPL304110, as a potent and selective inhibitor of fibroblast growth factor receptors FGFR (1-3).
Topics: Antineoplastic Agents; Benzimidazoles; Cell Proliferation; Drug Discovery; Humans; Protein Kinase Inhibitors; Pyrazoles; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3 | 2021 |
Other Studies
9 other study(ies) available for pd 173074 and azd4547
| Article | Year |
|---|---|
Discovery of Substituted 1H-Pyrazolo[3,4-b]pyridine Derivatives as Potent and Selective FGFR Kinase Inhibitors.
Topics: | 2016 |
Synthesis of novel arylaminoquinazolinylurea derivatives and their antiproliferative activities against bladder cancer cell line.
Topics: Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Quinazolines; Urea; Urinary Bladder Neoplasms | 2016 |
Transforming fusions of FGFR and TACC genes in human glioblastoma.
Topics: Aneuploidy; Animals; Antineoplastic Agents; Benzamides; Brain Neoplasms; Cell Transformation, Neoplastic; Chromosomal Instability; Enzyme Inhibitors; Fetal Proteins; Glioblastoma; Humans; Mice; Microtubule-Associated Proteins; Mitosis; Neoplasm Transplantation; Nuclear Proteins; Oncogene Fusion; Oncogene Proteins, Fusion; Piperazines; Protein Structure, Tertiary; Pyrazoles; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 3; Spindle Apparatus; Translocation, Genetic; Xenograft Model Antitumor Assays | 2012 |
Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.
Topics: Antineoplastic Agents; Benzamides; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Multiple Myeloma; Mutation; Neoplasms; Piperazines; Pyrazoles; Pyrimidines; Receptor Protein-Tyrosine Kinases; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Receptors, Fibroblast Growth Factor; Signal Transduction; Stomach Neoplasms; Urinary Bladder Neoplasms | 2013 |
Formation of a polarised primitive endoderm layer in embryoid bodies requires fgfr/erk signalling.
Topics: Animals; Benzamides; Biomarkers; Cell Line; Cell Lineage; Cell Polarity; Diphenylamine; Embryoid Bodies; Endoderm; Epithelial Cells; Extracellular Signal-Regulated MAP Kinases; GATA Transcription Factors; Gene Expression Regulation, Developmental; Homeodomain Proteins; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase Kinases; Nanog Homeobox Protein; Phosphorylation; Piperazines; Pyrazoles; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 1 | 2014 |
Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Isoxazoles; Molecular Targeted Therapy; Oxazoles; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 2; Receptors, Fibroblast Growth Factor; Resorcinols; Stomach Neoplasms; Transforming Growth Factor beta1; Triazoles | 2016 |
Multikinase activity of fibroblast growth factor receptor (FGFR) inhibitors SU5402, PD173074, AZD1480, AZD4547 and BGJ398 compromises the use of small chemicals targeting FGFR catalytic activity for therapy of short-stature syndromes.
Topics: Achondroplasia; Animals; Benzamides; Cartilage; Catalysis; Cells, Cultured; Chick Embryo; Chondrocytes; Humans; Mice; Phenylurea Compounds; Piperazines; Pyrazoles; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Signal Transduction; Syndrome | 2016 |
Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cell Line; Cell Line, Tumor; Gene Amplification; Gene Dosage; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunoblotting; In Situ Hybridization, Fluorescence; Lung Neoplasms; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, ErbB-2; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor alpha; Receptors, Fibroblast Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
SCLLTargeting FGFR1 to suppress leukemogenesis in syndromic and de novo AML in murine models.
Topics: Animals; Benzamides; Benzimidazoles; Carcinogenesis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Gene Expression Profiling; Humans; Leukemia; Mice; Molecular Targeted Therapy; Neoplasm Transplantation; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Quinolones; Receptor, Fibroblast Growth Factor, Type 1; Xenograft Model Antitumor Assays | 2016 |